EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation
Authors:
- Eskil EskilssonEEEskil Eskilsson
- Gro V. RoslandGRGro V. Rosland
- Krishna M. TalasilaKTKrishna M. Talasila
- Stian KnappskogSKStian Knappskog
- Olivier KeunenOKOlivier Keunen
- Andrea SottorivaASAndrea Sottoriva
- Sarah FoersterSFSarah Foerster
- Gergely SoleckiGSGergely Solecki
- Torfinn TaxtTTTorfinn Taxt
- Radovan JirikRJRadovan Jirik
- Sabrina FritahSFSabrina Fritah
- Patrick N. HarterPHPatrick N. Harter
Open Access
- 10 June 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 18 (12) , 1644-1655
Abstract
Amplification of the epidermal growth factor receptor (EGFR) and its mutant EGFRvIII are among the most common genetic alterations in glioblastoma (GBM), the most frequent and most aggressive primary brain tumor. In the present work, we analyzed the clonal evolution of these major EGFR aberrations in a small cohort of GBM patients using a unique surgical multisampling technique. Furthermore, we overexpressed both receptors separately and together in 2 patient-derived GBM stem cell lines (GSCs) to analyze their functions in vivo in orthotopic xenograft models. In human GBM biopsies, we identified EGFR amplification as an early event because EGFRvIII mutations emerge from intratumoral heterogeneity later in tumor development. To investigate the biological relevance of this distinct developmental pattern, we established experimental model systems. In these models, EGFR+ tumor cells showed activation of classical downstream signaling pathways upon EGF stimulation and displayed enhanced invasive growth without evidence of angiogenesis in vivo. In contrast, EGFRvIII+ tumors were driven by activation of the prototypical Src family kinase c-Src that promoted VEGF secretion leading to angiogenic tumor growth. The presented work shows that sequential EGFR amplification and EGFRvIII mutations might represent concerted evolutionary events that drive the aggressive nature of GBM by promoting invasion and angiogenesis via distinct signaling pathways. In particular, c-SRC may be an attractive therapeutic target for tumors harboring EGFRvIII as we identified this protein specifically mediating angiogenic tumor growth downstream of EGFRvIII.Keywords
Funding Information
- Research Council of Norway, The Norwegian Cancer Society, Helse Vest, Haukeland University Hospital
- Research Foundation, the Bergen Medical Research Foundation
- Italian Association for Cancer Research (AIRC 2013 IG 14042, GA102/12/2380)
- Ministry of Education, Youth, and Sports of the Czech Republic (LO1212)
This publication has 46 references indexed in Scilit:
- Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant gliomaMolecular Cancer, 2013
- EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesisActa Neuropathologica, 2013
- Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamicsProceedings of the National Academy of Sciences, 2013
- Single-Molecule Genomic Data Delineate Patient-Specific Tumor Profiles and Cancer Stem Cell OrganizationCancer Research, 2013
- Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastomaNeuro-Oncology, 2012
- Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastomaProceedings of the National Academy of Sciences, 2011
- EGF-Induced ERK Activation Promotes CK2-Mediated Disassociation of α-Catenin from β-Catenin and Transactivation of β-CateninMolecular Cell, 2009
- Fyn and Src Are Effectors of Oncogenic Epidermal Growth Factor Receptor Signaling in Glioblastoma PatientsCancer Research, 2009
- EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumorsNeuro-Oncology, 2009
- Angiogenesis-independent tumor growth mediated by stem-like cancer cellsProceedings of the National Academy of Sciences, 2006